Bullboard - Stock Discussion Forum Dynavax Technologies Corp DVAX

Healthcare Biotechnology

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company, which is engaged in developing and commercializing vaccines. The Company's products include HEPLISAV-B hepatitis B vaccine and CpG 1018. Its HEPLISAV-B ((Recombinant)(Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older... see more

Add To Watchlist

NDAQ:DVAX - Post Discussion

Dynavax Technologies Corp > Hep-b approval and Corona vaccine trial updates imminent

View:

Post by wmcvey on Dec 11, 2020 12:04pm

Hep-b approval and Corona vaccine trial updates imminent

More than doubling of the Hep-B vaccine market, Dynavax's primary revenue source, looks very likely: https://www.prnewswire.com/news-releases/european-chmp-adopts-positive-opinion-for-heplisav-b-dynavaxs-two-dose-adult-hepatitis-b-adjuvanted-vaccine-301190681.html

This, alongside news from the multiple Covid trials Dynavax contributed an adjuvant for, bodes well for a doubling of the stock once again. $5 to $10, as we saw in the summer, looks likely to me within the next quarter, depending on Covid results. This could be especially important in light of reported setbacks my vaccine giant GSK. Door is open build on success from Moderna and Pfizer.

246